Tempus AI (TEM) shares soared to an all-time high Thursday, extending their recent rally as the tech firm announced a collaboration with the nonprofit Institute for Follicular Lymphoma Innovation (IFLI) to develop targeted therapies for the disease.
Tempus said its data analytics platform Lens will be used in the collaboration to help researchers “derive AI-driven insights to accelerate the development of FL treatments in an effort to improve patient outcomes.”
“We are excited to work with IFLI and explore a new way of working with foundations to advance research,” said Tempus Chief Scientific Officer Kate Sasser, PhD. “By leveraging our combined expertise and reach, we aim to create a centralized and dynamic data library that enables researchers to better understand FL.”
Tempus shares were up nearly 15% to $84.85 Thursday afternoon after hitting an intraday record at $86. With Thursday’s gains, they’ve surged nearly 50% so far this month, and more than doubled in value from their IPO price of $37 last June.
:max_bytes(150000):strip_icc()/GettyImages-2197498676-9d903e87602842e9b8d8c57ee32f0919.jpg?w=1200&resize=1200,0&ssl=1&description=Tempus+AI+Stock+Soars+to+All-Time+High){kind=link}